Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets.

Trial Profile

Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2013

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Alfa Wassermann Inc
  • Most Recent Events

    • 30 Mar 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 12 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top